Similar articles

Abstract: We report that a 63-year-old Chinese female had acute myeloblastic leukemia (AML) in which trisomy 21 (+21) was found as the sole acquired karyotypic abnormality. The blasts were positive for myeloperoxidase, and the immunophenotype was positive for cluster of differentiation 19 (CD19), CD33, CD34, and human leukocyte antigens (HLA)-DR. The chromosomal analysis of bone marrow showed 47,XX,+21[2]/46,XX[18]. Fluorescent in situ hybridization (FISH) showed that three copies of AML1 were situated in separate chromosomes, and that t(8;21) was negative. The patient did not have any features of Down syndrome. A diagnosis of CD19-positive AML-M5 was established with trisomy 21 as a sole acquired karyotypic abnormality. The patient did not respond well to chemotherapy and died three months after the diagnosis. This is the first reported case of CD19-positive AML with trisomy 21 as the sole cytogenetic abnormality. The possible prognostic significance of the finding in AML with +21 as the sole acquired karyotypic abnormality was discussed.

[1] Arthur, D.C., Berger, R., Golomb, H.M., Swansbury, G.J., Reeves, B.R., Alimena, G., van den Berghe, H., Bloomfield, C.D., de la Chapelle, A., Dewald, G.W., et al., 1989. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet. Cytogenet., 40(2): 203-216.

[2] Ball, E.D., Davis, R.B., Griffin, J.D., Mayer, R.J., Davey, F.R., Arthur, D.C., Wurster-Hill, D., Noll, W., Elghetany, M.T., Allen, S.L., et al., 1991. Prognostic value of lymphocytic surface markers in acute myeloid leukemia. Blood, 77(10): 2242-2250.

[3] Berger, R., Flandrin, G., Bernheim, A., Le Coniat, M., Vecchione, D., Pacot, A., Derré, J., Daniel, M.T., Valensi, F., Sigaux, F., et al., 1987. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet. Cytogenet., 29(1):9-21.

[4] Bradstock, K., Matthews, J., Benson, E., Page, F., Bishop, J., 1994. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood, 84(4):1220-1225.

[5] Cortes, J.E., Kantarjian, H., O′Brien, S., Keating, M., Pierce, S., Freireich, E.J., Estey, E., 1995. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia, 9(1):115-117.

[6] Dewald, G.W., Diez-Martin, J.L., Steffen, S.L., Jenkins, R.B., Stupca, P.J., Burgert, E.O.Jr., 1990. Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome. Am. J. Med. Genet., 37(s2): 247-250.

[7] Drexler, H.G., Thiel, E., Ludwig, W.D., 1993. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia, 7(4):489-498.

[8] Gallego, M., Solé, F., Acín, P., Florensa, L., Sans-Sabrafèn, J., Woessner, S., 1997. A new case of trisomy 21 in a patient with an acute nonlymphocytic leukemia (M5b). Cancer Genet. Cytogenet., 95(2):213-214.

[9] Hasle, H., Clemmensen, I.H., Mikkelsen, M., 2000. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet, 355(9199):165-169.

[10] Heim, S., Mitelman, F., 1986. Numerical chromosome aberrations in human neoplasia. Cancer Genet. Cytogenet., 22(2):99-108.

[11] Kita, K., Miwa, H., Nakase, K., Kawakani, K., Kobayashi, T., Shirakawa, S., Tanaka, I., Ohta, C., Tsutani, H., Oguma, S., et al., 1993. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood, 81(9):2399-2405.

[12] Kondo, H., Kobayashi, A., Iwasaki, H., 2001. Trisomy 21 as the sole acquired karyotypic abnormality in an adult patient with CD7-positive acute myeloid leukemia. Cancer Genet. Cytogenet., 127(1):77-79.

[13] Mitelman, F., 1994. Catalog of Chromosome Aberrations in Cancer, 5 Ed. Wiley-Liss, New York, p.849-874.

[14] Mitelman, F., Heim, S., Mandahl, N., 1990. Trisomy 21 in neoplastic cells. Am. J. Med. Genet., 37(s2):262-266.

[15] Raimondi, S.C., Pui, C.H., Head, D., Behm, F., Privitera, E., Roberson, P.K., Rivera, G.K., Williams, D.L., 1992. Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia. Leukemia, 6(3):171-175.

[16] Ravindranath, Y., Abella, E., Krischer, J.P., Wiley, J., Inoue, S., Harris, M., Chauvenet, A., Alvarado, C.S., Dnbowy, R., Ritchey, A.K., et al., 1992. Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 80(9):2210-2214.

[17] Sacchi, N., 1992. Down syndrome and chromosome 21 abnormalities in leukemia. Baillieres Clin. Haematol., 5(4):815-831.

[18] Saxena, A., Sheridan, D.P., Card, R.T., McPeek, A.M., Mewdell, C.C., Skinnider, L.F., 1998. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am. J. Hematol., 58(4):278-284.

[19] Schwarzinger, I., Valent, P., Koller, U., Marosi, C., Schneider, B., Haas, O., Knapp, W., Lechner, K., Bettelheim, P., 1990. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J. Clin. Oncol., 8(3):423-430.

[20] Shaffer, L.G., Tommerup, N., 2005. Numerical Chromosome Abnormalities. In: Shaffer, L.G., Tommerup, N. (Eds.), ISCN (2005): An International System for Human Cytogenetic Nomenclature. S. Karger, Basel Switzerland, p.55-58.

[21] Shen, J.J., Williams, B.J., Zipursky, A., Doyle, J., Sherman, S.L., Jacobs, P.A., Shugar, A.L., Soukup, S.W., Hassold, T.J., 1995. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am. J. Hum. Genet., 56(4):915-925.

[22] Solary, E., Casasnovas, R.O., Campos, L., Bene, M.C., Faure, G., Maingon, P., Falkenrodt, A., Lenormand, B., Genetet, N., 1992. Surface markers in adult acute myeloblastic leukemia: correlation of CD19⁺, CD34⁺ and CD14⁺/ DR—phenotypes with shorter survival. Groupe d′Etude Immunologique des Leucémies (GEIL). Leukemia, 6(5): 393-399.

[23] Udayakumar, A.M., Pathare, A.V., Muralitharan, S., Alghzaly, A.A., Alkindi, S., Raeburn, J.A., 2007. Trisomy 21 as a sole acquired abnormality in an adult Omani patient with CD7- and CD9-positive acute myeloid leukemia. Arch. Med. Res., 38(7):797-802.

[24] Wan, T.S., Au, W.Y., Chan, J.C., Chan, L.C., Ma, S.K., 1999. Trisomy 21 as the sole acquired karyotypic abnormality in acute myeloid leukemia and myelodysplastic syndrome. Leuk. Res., 23(11):1079-1083.

[25] Watson, M.S., Carroll, A.J., Shuster, J.J., Steuber, C.P., Borowitz, M.J., Behm, F.G., Pullen, D.J., Land, V.J., 1993. Trisomy 21 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group Study (8602). Blood, 82(10):3098-3102.

[26] Wei, C.H., Yu, I.T., Tzeng, C.H., Fan, F.S., Hsieh, R.K., Chiou, T.J., Liu, J.H., Chen, P.M., 1996. Trisomy 21 in acute myeloid leukemia. Cancer Genet. Cytogenet., 86(2): 177-180.

[27] Yamamoto, K., Nagata, K., Hamaguchi, H., 2002. A new case of CD7-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired abnormality. Cancer Genet. Cytogenet., 133(2):183-184.